Is NDSN a good stock to buy?
Nordson Corporation · end-of-day data as of Nov 13, 2026
- FCF yield+4.0%
- Trendbullish
- MAs4 of 4
- MACD0.11
- Earnings in32d
- P/E32.8x
- RSI50
- Support-5.5%
- Resistance+2.1%
- Off 52w high-4.2%
- Volume0.6x
- Bollingerupper half
- News0.00
- ConsensusHold · 7
- PT$332.67 +2.4%
- 52w range$223–$339
- ATR+2.5%
- Off ATH-4.2%
- MA20×50↓ in ~5d
- P/E vs own+11.5%
- P/E vs sector+20.0%
- Insiders-$876K
- Sector▼ -11.7%
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Nordson a good stock to buy?
Nordson is strong on 3 of the 5 questions about the business. The price is about usual: 32.8 times its earnings, near its 3-year median of 29.6 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage hard to copy
- Economics very profitable
- Execution mixed
- Fragility sturdy
- Price about usual
NDSN sales growth revenue growth
+3%a year, for the last 3 yearsNordson's sales grew 3% a year for 3 years, to $2.79B in fiscal 2025.
NDSN analysts' forecast revenue estimates
+9%the sales they expect next fiscal year, on the lastAnalysts expect Nordson's sales to grow 9% to $3.06B in fiscal 2026 (6 analysts).
NDSN competitors
pretickt analysis+7%its sales in 12 months, on a year before
Nordson's sales grew 7% in the 12 months to Jul 31, 2026, faster than IDEX (+7%), Lennox (+2%) and Xylem (+2%), slower than Symbotic (+21%).
NDSN sales by business revenue by segment
55%of its sales from Industrial Precision SolutionsIndustrial Precision Solutions brought Nordson 55% of its sales in fiscal 2024; Medical And Fluid Solutions 26%.
NDSN return on capital ROIC
pretickt analysis16%earned before tax on the money invested in itNordson earned 16% before tax on the capital invested in it in the 12 months to Jul 31, 2026; Lennox 31%, IDEX 15% and Xylem 11%.
NDSN margin on each sale gross margin
55%left after making the productNordson kept 55% of each sale after making the product in the 12 months to Jul 31, 2026; its competitors' median is 36%.
NDSN margin after costs profit margin
27%of sales left after running the businessNordson's operating margin was 27% in the 12 months to Jul 31, 2026, against 27% in fiscal 2022.
NDSN cash generated free cash flow
$728Mcash left after investing, last 12 monthsNordson generated $728M of free cash flow in the 12 months to Jul 31, 2026, more than its reported profit.
NDSN earnings vs estimates
6 of 8quarters above the analysts' estimateNordson beat the analysts' profit estimate in 6 of its last 8 quarters, the latest on Aug 19, 2026.
NDSN insider selling
-$23.49Msold, net, by its executives in 12 monthsNordson's executives and directors sold a net $23.49M of shares in the 12 months to Nov 13, 2026; none bought.
NDSN number of employees
0%about as many people as a year beforeNordson had 8,000 employees at the end of fiscal 2025, about as many as a year before.
NDSN CEO pay
$8.15Mfor fiscal 2025, 62% of it in stock and optionsNordson paid its CEO $8.15M for fiscal 2025, 62% of it in stock and options.
NDSN financial health Altman Z-score
6.3Altman Z-score, safe above 3Nordson's Altman Z-score is 6.3 (Nov 13, 2026), above 3, where the safe zone starts.
NDSN quality checks Piotroski score
9 of 9checks passedNordson passes all 9 Piotroski checks in the 12 months to Jul 31, 2026.
NDSN biggest customers
under 10%of sales from any one customerNo customer made 10% of Nordson's sales in fiscal 2025.
NDSN in past recessions
pretickt analysis-27%its sales in the worst oneNordson's sales fell in each of the last 2 US recessions, by as much as 27% in fiscal 2009.
NDSN price vs profit P/E ratio
32.8×a year's earningsNordson's P/E ratio is 32.8 (Nov 13, 2026), near its 3-year median of 29.6.
NDSN price vs competitors
pretickt analysis32.8×a year's earnings, against its competitorsInvestors pay 32.8 times Nordson's earnings (Nov 13, 2026), more than for Xylem (20.8) and Lennox (16.3), less than for Symbotic (376.1) and IDEX (33.0).
NDSN analysts' target price target
+2%to their average targetAnalysts' average price target for Nordson is $333, 2% above the Nov 13, 2026 close of $324.74.
NDSN growth priced in fair value
pretickt analysis+10%a year, for ten years, to be worth the priceAt $324.74 a share, Nordson's free cash flow must grow about 10% a year for ten years to be worth the price (Nov 13, 2026).
What is Nordson's P/E ratio?
Nordson's P/E ratio is 32.8 (Nov 13, 2026), near its 3-year median of 29.6. Investors pay 32.8 times Nordson's earnings (Nov 13, 2026), more than for Xylem (20.8) and Lennox (16.3), less than for Symbotic (376.1) and IDEX (33.0).
Who are Nordson's biggest competitors?
pretickt compares Nordson with IDEX, Symbotic, Xylem and Lennox. Nordson's sales grew 7% in the 12 months to Jul 31, 2026, faster than IDEX (+7%), Lennox (+2%) and Xylem (+2%), slower than Symbotic (+21%).
Is Nordson profitable?
Nordson's operating margin was 27% in the 12 months to Jul 31, 2026, against 27% in fiscal 2022. Nordson generated $728M of free cash flow in the 12 months to Jul 31, 2026, more than its reported profit.
Are insiders selling Nordson stock?
Nordson's executives and directors sold a net $23.49M of shares in the 12 months to Nov 13, 2026; none bought.
How does Nordson make money?
Industrial Precision Solutions brought Nordson 55% of its sales in fiscal 2024; Medical And Fluid Solutions 26%.
How many employees does Nordson have?
Nordson had 8,000 employees at the end of fiscal 2025, about as many as a year before.
Who are Nordson's biggest customers?
No customer made 10% of Nordson's sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.